Royal London Asset Management Ltd. Has $100.63 Million Stock Holdings in Alnylam Pharmaceuticals, Inc. $ALNY

Royal London Asset Management Ltd. trimmed its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 1.6% during the fourth quarter, HoldingsChannel.com reports. The firm owned 253,072 shares of the biopharmaceutical company’s stock after selling 4,241 shares during the period. Royal London Asset Management Ltd.’s holdings in Alnylam Pharmaceuticals were worth $100,634,000 at the end of the most recent quarter.

Other hedge funds have also recently made changes to their positions in the company. Caitong International Asset Management Co. Ltd acquired a new stake in shares of Alnylam Pharmaceuticals during the third quarter valued at about $29,000. HM Payson & Co. acquired a new position in shares of Alnylam Pharmaceuticals in the fourth quarter worth approximately $27,000. Ameriflex Group Inc. acquired a new position in shares of Alnylam Pharmaceuticals in the third quarter worth approximately $32,000. Aster Capital Management DIFC Ltd acquired a new position in shares of Alnylam Pharmaceuticals in the third quarter worth approximately $36,000. Finally, Manchester Capital Management LLC lifted its stake in shares of Alnylam Pharmaceuticals by 600.0% in the fourth quarter. Manchester Capital Management LLC now owns 84 shares of the biopharmaceutical company’s stock worth $33,000 after acquiring an additional 72 shares during the period. 92.97% of the stock is owned by institutional investors and hedge funds.

Alnylam Pharmaceuticals Trading Down 2.3%

NASDAQ ALNY opened at $282.85 on Friday. The company has a market cap of $37.76 billion, a price-to-earnings ratio of 77.28 and a beta of 0.29. Alnylam Pharmaceuticals, Inc. has a 52 week low of $281.77 and a 52 week high of $495.55. The business has a 50 day moving average price of $304.31 and a 200-day moving average price of $343.68. The company has a quick ratio of 3.06, a current ratio of 3.13 and a debt-to-equity ratio of 0.94.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings data on Thursday, April 30th. The biopharmaceutical company reported $1.99 EPS for the quarter, beating the consensus estimate of $0.87 by $1.12. The firm had revenue of $1.17 billion during the quarter, compared to the consensus estimate of $1.12 billion. Alnylam Pharmaceuticals had a return on equity of 85.76% and a net margin of 11.72%.The company’s quarterly revenue was up 96.4% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.44) earnings per share. As a group, equities analysts expect that Alnylam Pharmaceuticals, Inc. will post 7.47 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts recently commented on the company. Canaccord Genuity Group lifted their price objective on Alnylam Pharmaceuticals from $415.00 to $429.00 and gave the stock a “buy” rating in a research note on Tuesday, February 17th. Jefferies Financial Group reaffirmed a “hold” rating and issued a $330.00 price objective (down from $522.00) on shares of Alnylam Pharmaceuticals in a research note on Monday, March 16th. Citigroup assumed coverage on Alnylam Pharmaceuticals in a research note on Tuesday, May 19th. They issued a “buy” rating and a $380.00 price objective on the stock. Chardan Capital reissued a “buy” rating and issued a $425.00 price target on shares of Alnylam Pharmaceuticals in a research note on Wednesday, March 25th. Finally, Truist Financial dropped their price target on Alnylam Pharmaceuticals from $515.00 to $505.00 and set a “buy” rating on the stock in a research note on Monday, April 13th. Two investment analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and six have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $463.13.

Insider Buying and Selling at Alnylam Pharmaceuticals

In related news, Director David E. I. Pyott sold 3,830 shares of the company’s stock in a transaction on Monday, June 1st. The stock was sold at an average price of $299.18, for a total transaction of $1,145,859.40. Following the completion of the sale, the director owned 1,582 shares in the company, valued at approximately $473,302.76. This represents a 70.77% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Melissa Mclaughlin sold 2,286 shares of the company’s stock in a transaction on Monday, April 6th. The stock was sold at an average price of $330.42, for a total value of $755,340.12. Following the sale, the insider owned 9,443 shares of the company’s stock, valued at $3,120,156.06. This trade represents a 19.49% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 7,740 shares of company stock valued at $2,420,214 in the last quarter. 0.86% of the stock is currently owned by corporate insiders.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.